Thomas Wegge

This inventor holds 38 USPTO granted patents and 26 published patent applications, plus 17 CIPO patents and 20 EPO patents, primarily in Controlled-Release Therapies. Top assignees: Ascendis Pharma A/s, Ascendis Pharma Bone Diseases A/s, Ascendis Pharma Endocrinology Division A/s. Active years: 2011-2025.

USPTO Granted Patents = 38 (Patent Applications = 26)

% Patents Active = 78.9

CIPO Patents = 17 (Patent Applications = 5)

EPO Patents = 20 (Patent Applications = 27)

Average Co-Inventor Count = 5.7

ph-index = 8

Forward Citations = 316(Granted Patents)

Location History:

Heidelberg/Ziegelhausen, DE (2011 - 2018)
Heidelberg, DE (2011 - 2024)

Company Filing History:

Ascendis Pharma Bone Diseases A/s

patents

7 out of 9

Ascendis Pharma Endocrinology Division A/s

patents

4. 4 out of 1,855

Sanofi-A Ventis Deutschland Gmbh

Ascendis Pharma Growth Disorders A/s

patents

7. 2 out of 2

Ascendis Pharma Growth Disorders Division A/s

patents

8. 1 out of 1

Ascendis Pharma Endocrinology Division

patent

9. 1 out of 1

Complex Biosystems Gmbh

patent

Years Active: 2011-2025

Loading Chart...

Areas of Expertise:

Controlled-Release

PTH Compounds

Growth Hormone

Prodrugs

PEGylation

Hydrogel Formulations

Polymeric Carriers

Transient Linkers

Sustained Release

Insulin Linker

Protein-Proteophore

Aliphatic Linkers

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12453778 - Incremental dose finding in controlled-release PTH compounds (2025-10-28),

2. 12295989 - Controlled-release PTH compound (2025-05-13),

3. 12274737 - PEGylated recombinant human growth hormone compounds (2025-04-14),

4. 12226457 - Dry growth hormone composition transiently linked to a polymer carrier (2025-02-18),

5. 12214020 - PTH prodrugs (2025-02-04),

6. 12133883 - Polymeric hGH prodrugs (2024-11-05),

7. 11918628 - Controlled-release PTH compound (2024-03-05),

8. 11890326 - Controlled-release PTH compound (2024-02-06),

9. 11857603 - PTH compounds with low peak-to-trough ratios (2024-01-02),

10. 11793861 - PTH prodrugs (2023-10-24),

11. 11759504 - PTH compounds with low peak-to-trough ratios (2023-09-19),

12. 11311604 - Controlled-release CNP agonists with low NPR-C binding (2022-04-26),

13. 11224661 - Controlled-release CNP agonists with increased NEP stability (2022-01-18),

14. 10960053 - PEGylated recombinant human growth hormone compounds (2021-03-30),

15. 10799563 - Polymeric hGH prodrugs (2020-10-13),

Title: Thomas Wegge - Innovative Inventor from Heidelberg

Introduction: Thomas Wegge is a renowned inventor hailing from Heidelberg, Germany, known for his groundbreaking contributions to various fields of technology and science.

Latest Patents: Thomas Wegge holds several patents in the areas of renewable energy, sustainable materials, and advanced robotics, showcasing his commitment to creating a more efficient and eco-friendly future.

Career Highlights: With a career spanning over two decades, Thomas Wegge has worked with leading research institutions and tech companies to develop cutting-edge solutions that have revolutionized industries worldwide.

Collaborations: Throughout his career, Thomas Wegge has collaborated with top engineers, scientists, and designers, fostering a culture of innovation and excellence in all his projects.

Conclusion: Thomas Wegge's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs, making him a true pioneer in the world of technology.